in vitro PHARMACOLOGY 2011 CATALOG - Cerep

More documents

Recommendations

Info

188 in vitro pharmacology 2011 catalog ❚ arachidonic acid metabolite secretion PGI 2 secretion cellul ar Ref. 0240 Activator effect Ref. 0241 Inhibitor effect [CUSTOM OFFER] Source TXB 2 secretion (inhibitor effect) cellul ar Ref. 2006 [CUSTOM OFFER] HUV-EC-C Measured product 6ketoPGF 1α Detection method EIA Activator effect Control thrombin (0.3 U/mL) Reference thrombin (EC 50 : 0.04 U/mL) Inhibitor effect Stimulant human thrombin (0.3 U/mL) Reference indomethacin (IC 50 : 8.6 nM) Zavoico, G.B. et al. (1989) J. Immunol., 142: 3993-3999. ❚ This model should be used to test pro-inflammatory drugs. Source differentiated HL-60 Stimulant A23187 (5 µM) Measured product TXB 2 Detection method EIA Reference indomethacin (IC 50 : 4.7 nM) [Solvent] must be kept ≤ 0.1% Zaitsu, M. et al. (2002) Prost. Leuk. Essent. Fatty Acids, 67: 405-410. [Solvent] must be kept 0.1% ❚ Chemokine secretion IL-8 secretion (inhibitor effect) cellul ar Ref. 0272 [CUSTOM OFFER] Source PBMC Stimulant LPS (1 µg/mL) Measured product IL-8 Detection method EIA Reference dexamethasone (IC 50 : 8.4 nM) [Solvent] must be kept ≤ 0.1% Schindler, R. et al. (1990) Blood, 75: 40-47. ❚ Cytokine secretion IFN-g secretion (inhibitor effect) cellul ar Ref. 0368 [CUSTOM OFFER] Source Stimulant Measured product PBMC PHA (2 µg/mL) IFN-γ Detection method EIA Reference dexamethasone (IC 50 : 3.5 nM) [Solvent] must be kept ≤ 0.1% Andre, F. et al. (1996) Allergy, 51: 350-355. IFN-γ secretion (% of control) 100 50 0 -10 -9 -8 -7 -6 -5 log [drug] (M) dexamethasone IL-1β secretion (inhibitor effect) cellul ar Ref. 0262 [CUSTOM OFFER] Source Stimulant Measured product PBMC LPS (1 µg/mL) IL-1β Detection method EIA Reference cycloheximide (IC 50 : 230 nM) [Solvent] must be kept ≤ 0.1% Schindler, R. et al. (1990) Blood, 75: 40-47. IL-1β secretion (% of control) 100 50 0 -9 -8 -7 -6 -5 log [drug] (M) cycloheximide
189 cytokine secretion ❚ IL-2 secretion (inhibitor effect) cellul ar Ref. 0263 [CUSTOM OFFER] Source Stimulant Measured product PBMC PHA (20 µg/mL) IL-2 Detection method EIA Reference dexamethasone (IC 50 : 9 nM) [Solvent] must be kept ≤ 0.1% Konno, S. et al. (1994) Eur. J. Pharmacol., 264: 265-268. IL-2 secretion (% of control) 100 50 0 -11 -10 -9 -8 -7 -6 -5 log [drug] (M) dexamethasone Cerep services Receptors IL-4 secretion (inhibitor effect) cellul ar Ref. 0264 [CUSTOM OFFER] Source PBMC Stimulant ConA (20 µg/mL) Measured product IL-4 Detection method EIA Reference dexamethasone (IC 50 : 4.8 nM) [Solvent] must be kept ≤ 0.1% Endo, H. et al. (1993) Int. Arch. Allergy Immunol., 101: 425-430. IL-4 secretion (% of control) 100 50 0 -10 -9 -8 -7 -6 log [drug] (M) dexamethasone Ion channels Transporters IL-5 secretion (inhibitor effect) cellul ar Ref. 0265 [CUSTOM OFFER] Source PBMC Stimulant ConA (20 µg/mL) Measured product IL-5 Detection method EIA Reference dexamethasone (IC 50 : 2.4 nM) [Solvent] must be kept ≤ 0.1% Endo, H. et al. (1993) Int. Arch. Allergy Immunol., 101: 425-430. IL-5 secretion (% of control) 100 50 0 -11 -10 -9 -8 -7 -6 -5 log [drug] (M) dexamethasone Kinases Epigenetic & DNA-related enzymes IL-6 secretion (inhibitor effect) cellul ar Ref. 0269 [CUSTOM OFFER] Source PBMC Stimulant LPS (1 µg/mL) Measured product IL-6 Detection method EIA Reference dexamethasone (IC 50 : 5 nM) [Solvent] must be kept ≤ 0.1% Schingler, R. et al. (1990) Blood, 75: 40-47. IL-6 secretion (% of control) 100 50 0 -10 -9 -8 -7 -6 log [drug] (M) dexamethasone Other enzymes Specialized cellular assays IL-10 secretion (inhibitor effect) cellul ar Ref. 0273 [CUSTOM OFFER] Source PBMC Stimulant PHA (3 µg/mL) Measured product IL-10 Detection method EIA Reference dexamethasone (IC 50 : 15 nM) [Solvent] must be kept ≤ 0.1% Rigano, R. et al. (1995) Clin. Exp. Immunol., 99: 433-439. IL-10 secretion (% of control) 100 50 0 -10 -9 -8 -7 -6 log [drug] (M) dexamethasone Standard profiles Testing conditions TNF-α secretion (inhibitor effect) cellul ar Ref. 0259 [CUSTOM OFFER] Source Stimulant Measured product PBMC LPS (1 µg/mL) TNF-α Detection method EIA Reference dexamethasone (IC 50 : 6 nM) [Solvent] must be kept ≤ 0.1% Schindler, R. et al. (1990) Blood, 75: 40-47. TNFα secretion (% of control) 100 50 0 -10 -9 -8 -7 -6 log [drug] (M) dexamethasone Ordering information Assay list & index
Page 1 and 2:
in vitro pharmacology 2011 catalog
Page 3 and 4:
Cerep services p. 4 Receptors [GPC
Page 5 and 6:
5 ❚ tool-box for cell-based assay
Page 7 and 8:
7 ❚ profile design Cerep offers a
Page 9 and 10:
9 ❚ data online A powerful web-ba
Page 11 and 12:
11 in vitro pharmacology assays Rec
Page 13 and 14:
13 Cerep services receptors Recept
Page 15 and 16:
15 Adenosine ❚ A 2B - antagonist
Page 17 and 18:
17 alpha 1B - antagonist radioligan
Page 19 and 20:
19 adrenergic ❚ alpha 2C - antago
Page 21 and 22:
adrenergic ❚ 21 beta 3 cellul ar
Page 23 and 24:
-12 -11 -10 -9 -8 -7 -6 -5 -4 -3 bo
Page 25 and 26:
adykinin ❚ 25 B 2 cellul ar Ref.
Page 27 and 28:
27 ❚ cannabinoid CB 1 - agonist r
Page 29 and 30:
29 chemokines ❚ CCR2 cellul ar Re
Page 31 and 32:
31 cholecystokinin ❚ CCK 2 (CCK B
Page 33 and 34:
33 dopamine ❚ D 2S - antagonist r
Page 35 and 36:
dopamine ❚ 35 D 5 cellul ar Ref.
Page 37 and 38:
37 Cerep services ❚ Free fatty ac
Page 39 and 40:
39 galanin ❚ GAL 2 - agonist radi
Page 41 and 42:
41 ❚ Growth hormone-releasing hor
Page 43 and 44:
43 H 3 - agonist radioligand Source
Page 45 and 46:
45 leukotrienes ❚ CysLT 2 (LTC 4
Page 47 and 48:
melanin concentrating hormone ❚
Page 49 and 50:
49 ❚ melatonin Cerep services MT
Page 51 and 52:
51 M 2 - antagonist radioligand bin
Page 53 and 54:
53 muscarinic ❚ M 5 - antagonist
Page 55 and 56:
55 NK 3 - agonist radioligand bindi
Page 57 and 58:
neuropeptide y ❚ 57 Y 1 cellul a
Page 59 and 60:
59 Cerep services ❚ opioid and op
Page 61 and 62:
61 NOP (ORL1) - agonist radioligand
Page 63 and 64:
63 platelet activating factor ❚ P
Page 65 and 66:
65 prostanoid ❚ EP 4 - agonist ra
Page 67 and 68:
67 proteinase-activated ❚ PAR2 ce
Page 69 and 70:
serotonin ❚ 69 5-HT 1A cellul ar
Page 71 and 72:
71 serotonin ❚ 5-HT 2B - agonist
Page 73 and 74:
73 5-HT 7 - agonist radioligand bin
Page 75 and 76:
75 ❚ thyrotropin releasing hormon
Page 77 and 78:
77 ❚ vasopressin Cerep services O
Page 79 and 80:
Page 81 and 82:
81 LXRb - agonist radioligand bindi
Page 83 and 84:
Page 85 and 86:
85 gaba ❚ GABA A1 (a1, b2, g2) -
Page 87 and 88:
87 glycine (strychnine-insensitive)
Page 89 and 90:
89 ❚ Melatonin MT 3 (ML 2 ) - ago
Page 91 and 92:
91 ❚ Sigma Cerep services sigma (
Page 93 and 94:
93 Cerep services [Voltage-gated ch
Page 95 and 96:
voltage-gated channels [K + channel
Page 97 and 98:
transient receptor potential channe
Page 99 and 100:
99 kainate - agonist radioligand bi
Page 101 and 102:
101 ❚ purinergic channels Cerep s
Page 103 and 104:
103 Cerep services transporters Rec
Page 105 and 106:
105 norepinephrine ❚ norepinephri
Page 107 and 108:
107 Cerep services Kinases Receptor
Page 109 and 110:
109 DDR2 kinase Ref. 2783 Q 3 weeks
Page 111 and 112:
111 protein-tyrosine kinases [Rtk]
Page 113 and 114:
113 FLT-3 kinase Ref. 2866 Q 3 week
Page 115 and 116:
115 KDR kinase (VEGFR2) Ref. 2864 Q
Page 117 and 118:
117 TRKB Ref. 2902 Q 3 weeks Includ
Page 119 and 120:
119 protein-tyrosine kinases [Ctk]
Page 121 and 122:
121 JAK1 Ref. 2619 Q 3 weeks Includ
Page 123 and 124:
123 TXK Ref. 2786 Q 3 weeks Include
Page 125 and 126:
125 CDK6 (cycD3) Ref. 2909 Q 3 week
Page 127 and 128:
protein-SERINE/THREONINE kinases [C
Page 129 and 130:
129 JNK3 Ref. 2916 Q 3 weeks Includ
Page 131 and 132:
131 CaMK1d Ref. 2922 Q 3 weeks Incl
Page 133 and 134:
133 MAPKAPK2 Ref. 3367 Q 3 weeks I
Page 135 and 136:
135 PhKg1 Ref. 2745 Q 3 weeks Inclu
Page 137 and 138: 137 ❚ protein-SERINE/THREONINE ki
Page 139 and 140: 139 MSK1 Ref. 1724 Q 3 weeks Source
Page 141 and 142: 141 PKCe Ref. 2044 Q 3 weeks PKCz R
Page 143 and 144: 143 ROCK2 Ref. 2884 Q 3 weeks Inclu
Page 145 and 146: 145 COT kinase (MAP3K8) Ref. 2003 Q
Page 147 and 148: 147 MKK6/p38a (mutant active) Ref.
Page 149 and 150: 149 ❚ protein-SERINE/THREONINE ki
Page 151 and 152: 151 RAF-1/MEK1 Ref. 1703 Q 3 weeks
Page 153 and 154: 153 other kinases ❚ MYT1 kinase R
Page 155 and 156: 155 other kinases ❚ TBK1 Ref. 33
Page 157 and 158: 157 Cerep services Epigenetic & DNA
Page 159 and 160: 159 HDACs ❚ HDAC3 Ref. 2083 Q 3 w
Page 161 and 162: 161 HDACs ❚ sirtuin 3 Source Subs
Page 163 and 164: 163 Cerep services Other enzymes Re
Page 165 and 166: 165 phosphatases ❚ phosphatase LA
Page 167 and 168: 167 phosphatase SHP2 (PTPN11) Sourc
Page 169 and 170: 169 caspase-3 ❚ Cysteine protease
Page 171 and 172: 171 proteases [aspartic proteases]
Page 173 and 174: 173 proteases [metalloproteases]
Page 175 and 176: phosphodiesterases ❚ 175 PDE4A 1
Page 177 and 178: 177 no synthases ❚ inducible NOS
Page 179 and 180: 179 ❚ Monoamine & neurotransmitte
Page 181 and 182: 181 Cerep services ❚ Transduction
Page 183 and 184: 183 miscellaneous enzymes ❚ carbo
Page 185 and 186: 185 Specialized cellular assays The
Page 187: 187 ion transport systems ❚ Na +
Page 191 and 192: 191 expression of endothelial adhes
Page 193 and 194: 193 PDGF-stimulated Balb/c 3T3 prol
Page 195 and 196: 195 cerep Standard profiles ExpresS
Page 197 and 198: 197 ❚ Cellular functional GPCR pr
Page 199 and 200: Cerep standard profiles ❚ 199 Dr
Page 201 and 202: Cerep standard profiles ❚ 201 Sa
Page 203 and 204: 203 testing conditions Binding, enz
Page 205 and 206: 205 The reference compound for each
Page 207 and 208: 207 ordering information Quotation
Page 209 and 210: 209 REQUESTED COMPOUND INFORMATION
Page 211 and 212: shipment instructions ❚ 211 For
Page 213 and 214: 213 assay list & index
Page 215 and 216: 215 CDK5/p35 124 CDK6 (cycD3) 125 C
Page 217 and 218: 217 MMP-3 172 MMP-7 172 MMP-8 172 M
Page 219 and 220: contacts ❚ france [Laboratories]
show all

in vitro PHARMACOLOGY 2011 CATALOG - Cerep

Create successful ePaper yourself

Delete template?

Save as template?